Cyclooxygenase 2 genotypes influence prostate cancer susceptibility in Japanese Men

Abstract

This study aims to evaluate the relationship between the cyclooxygenase 2 (COX2) G1195A (rs689465) polymorphism and the risk of prostate cancer in a Japanese population and the associations between COX2 polymorphisms and clinicopathological characteristics, including Gleason grade and prostate-specific antigen (PSA) grade. We recruited 134 patients with prostate cancer and 86 healthy controls matched for age and smoking status. The COX2 G1195A polymorphism status was determined by polymerase chain reaction and restriction fragment length polymorphism analysis. Genotype distributions (p = 0.028) and allelic frequencies (p = 0.014) differed significantly between prostate cancer and control groups in terms of the COX2 G1195A polymorphism (Pearson's χ (2) test). Logistic regression analysis of case and control outcomes showed an odds ratio between the GG and AA genotypes of 3.15 (95% confidence interval = 1.27-8.08, p = 0.014), indicating an increased risk of prostate cancer associated with the AA genotype. Subset analysis revealed no significant associations between this polymorphism and clinicopathological characteristics of prostate cancer. This study demonstrated a relationship between the COX2 G1195A variant and prostate cancer risk. This polymorphism may merit further investigation as a potential genomic marker for the early detection of prostate cancer. Our results support the hypothesis that rs689465 influences susceptibility to prostate cancer; however, prostate cancer progression was not associated with rs689465 in a Japanese population.

Genetic Variations in Inflammatory Response Genes and Their Association with the Risk of Prostate Cancer

“…Our study is the first to evaluate the association between COX-1 (50C>T) polymorphism and prostate cancer risk, whereas several previous reports were available for the association between COX-2 (-1195G>A) polymorphism and prostate cancer risk. Our study results were in agreement with Sugie et al [ 28 ] in a Japanese population, but Wu et al (Taiwan) [ 29 ], Cheng et al (USA) [ 30 ], and Kopp et al (Denmark) [ 13 ] showed the absence of risk association between COX-2 (-1195G>A) polymorphism and prostate cancer risk.…”

PSCA, Cox-2, and Ki-67 are independent, predictive markers of biochemical recurrence in clinically localized prostate cancer: a retrospective study

“…This results in hyperproliferation, transformation, tumor growth, invasion, and metastasis, thus potentially increasing the risk for PCa 19. One study reported Cox-2 overexpression not in tumor tissue but rather in proliferative inflammatory atrophy, a putative precursor lesion of PCa with a high correlation with HGPIN 2021. In addition, a recent review identified E-cadherin, a protein regulated by Cox-2, as a prognostic indicator in PCa with a strong correlation between E-cadherin dysfunction and BCR using TMAs in patients with clinically localized PCa after RP 14…”

Functional expression of TLR9 in esophageal cancer

“…It also inhibits apoptosis of cancer cells, reduces cell adhesion and induces angiogenesis, making it easier for the cancer cells to invade small blood vessels and lymphatic tube and metastasize (31,32). COX-2 has been extensively studied as an inducible expression protein and has been detected in various tumor tissues such as pancreatic cancer, colorectal carcinoma, non-small lung cancer positively correlates with tumor invasion and lymphatic metastasis (33,34). We then detected the effects of CpG ODN and CQ on mRNA expression of MMP-2, MMP-7 and COX-2.…”